Holen Sie sich die Stockscreener-App
44.26
0.53%
-0.237
Schlusskurs vom Vortag:
$44.50
Offen:
$44.64
24-Stunden-Volumen:
489.22K
Relative Volume:
0.18
Marktkapitalisierung:
$11.87B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
25.01
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
+0.69%
1M Leistung:
-5.03%
6M Leistung:
-2.50%
1J Leistung:
+29.70%
1-Tages-Spanne:
$44.21
$45.37
1-Wochen-Bereich:
$43.00
$45.41
52-Wochen-Spanne:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.27 | 11.93B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
RBC Capital Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $45 - 富途资讯
Exelixis: High-Growth Oncology Name Trading At A Discount (NASDAQ:EXEL) - Seeking Alpha
Precision Trading with Exelixis Inc. (EXEL) Risk Zones - Stock Traders Daily
How The New Price Target Is Shaping The Exelixis (EXEL) Investment Story - Yahoo Finance
Investing in Exelixis (NASDAQ:EXEL) Three Years Ago Would Have Delivered You a 152% Gain - 富途资讯
Exelixis earns IBD stock rating upgrade - MSN
Exelixis Earns IBD Stock Rating Upgrade - Investor's Business Daily
Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch - Insider Monkey
Exelixis, Inc. (EXEL) Investor Outlook: Robust Revenue Growth and Strategic Partnerships Fuel Future Potential - DirectorsTalk Interviews
Top 10 Oncology Stocks to Buy Now - Insider Monkey
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup - Chartmill
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis, Inc. $EXEL Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by EULAV Asset Management - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL) - The Globe and Mail
Exelixis, Inc. (EXEL): A Bull Case Theory - Finviz
Growth Recap: Is Exelixis Inc a play on infrastructure spendingM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Meritage Portfolio Management Has $12.20 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
InSilico Lands Drug Discovery Deal After Hong Kong IPO - Benzinga
Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL? - Sahm
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - MSN
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Finviz
Truist Securities raises Exelixis stock price target to $51 on oncology growth - Investing.com Canada
Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating - marketscreener.com
Exelixis, Inc. $EXEL Shares Sold by New York State Teachers Retirement System - MarketBeat
Citizens reiterates Market Outperform rating on Exelixis stock By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook - sharewise.com
EXEL: Franchise-focused oncology growth, strong 2025 results, and robust 2026 outlook driven by innovation - TradingView — Track All Markets
EXEL: Disciplined franchise strategy and strong pipeline drive growth in oncology markets - TradingView — Track All Markets
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Lobbying Update: $30,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis (NASDAQ:EXEL) Shares Gap DownShould You Sell? - MarketBeat
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results and 2026 Guidance - TradingView — Track All Markets
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Exelixis, Inc. (EXEL) Stock Analysis: Exploring The 3.32% Potential Upside - DirectorsTalk Interviews
Exelixis (EXEL) Poised for Growth with Promising Pipeline and Ma - GuruFocus
Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion$2.425 billion - marketscreener.com
Exelixis Says Fiscal Year 2026 Net Product Revenues Guidance Of $2.325 Billion$2.425 Billion - TradingView — Track All Markets
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 - Business Wire
Technical Reactions to EXEL Trends in Macro Strategies - Stock Traders Daily
Exelixis Provides 2026 Financial Guidance: Anticipates $2.525B to $2.625B in Revenue - Intellectia AI
EXELIXIS Q4 2025 Earnings Preview: Recent $EXEL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
CapEx per share of Exelixis, Inc. – FWB:EX9 - TradingView — Track All Markets
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Moran Wealth Management LLC Sells 23,495 Shares of Exelixis, Inc. $EXEL - MarketBeat
Commonwealth Equity Services LLC Has $15.76 Million Stake in Exelixis, Inc. $EXEL - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):